Trump’s drug-pricing order takes a hard line against pharma. Investors shrugged
President Trump on Monday unveiled his plan to dramatically overhaul the way the U.S. pays for drugs by lowering what he calls “inflated” prices to those paid by other countries. Pharma investors didn’t seem to care. The XBI, a closely tracked index of biotech stocks, was up over 4% by midday, while shares of large